Encelto for idiopathic macular telangiectasia type 2
Customize your policy alerts
Sign up for Bluecross Idaho Policy MP 5.01.679 alerts
Get alerted when Policy MP 5.01.679 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage of Encelto (revakinagene taroretcel-lwey), a surgically implanted gene-based therapy, for adults with idiopathic macular telangiectasia type 2. It defines initial-treatment medical-necessity criteria and circumstances in which repeat treatment or other requests are investigational or not medically necessary.
The policy was added to the medical policy library as a new policy effective November 1, 2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.